Vanguard Group’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $330M | Sell |
9,494,822
-42,249
| -0.4% | -$3.32M | ﹤0.01% | 1288 |
|
|
2025
Q3 | $793M | Sell |
9,537,071
-143,521
| -1% | -$10.4M | 0.01% | 815 |
|
|
2025
Q2 | $711M | Sell |
9,680,592
-301,376
| -3% | -$21.8M | 0.01% | 833 |
|
|
2025
Q1 | $1.14B | Sell |
9,981,968
-133,656
| -1% | -$8.14M | 0.02% | 605 |
|
|
2024
Q4 | $510M | Buy |
10,115,624
+109,294
| +1% | +$5.73M | 0.01% | 1026 |
|
|
2024
Q3 | $463M | Buy |
10,006,330
+452,624
| +5% | +$16.1M | 0.01% | 1091 |
|
|
2024
Q2 | $310M | Sell |
9,553,706
-12,076
| -0.1% | -$331K | 0.01% | 1243 |
|
|
2024
Q1 | $241M | Buy |
9,565,782
+28,250
| +0.3% | +$667K | ﹤0.01% | 1400 |
|
|
2023
Q4 | $310M | Buy |
9,537,532
+239,887
| +3% | +$6.59M | 0.01% | 1268 |
|
|
2023
Q3 | $253M | Sell |
9,297,645
-13,580
| -0.1% | -$393K | 0.01% | 1315 |
|
|
2023
Q2 | $207M | Sell |
9,311,225
-1,123,519
| -11% | -$25.9M | ﹤0.01% | 1459 |
|
|
2023
Q1 | $226M | Buy |
10,434,744
+89,714
| +0.9% | +$1.97M | 0.01% | 1389 |
|
|
2022
Q4 | $210M | Buy |
10,345,030
+12,953
| +0.1% | +$325K | 0.01% | 1401 |
|
|
2022
Q3 | $265M | Buy |
10,332,077
+458,414
| +5% | +$12.3M | 0.01% | 1212 |
|
|
2022
Q2 | $235M | Sell |
9,873,663
-565,089
| -5% | -$12.3M | 0.01% | 1329 |
|
|
2022
Q1 | $235M | Sell |
10,438,752
-358,725
| -3% | -$7.63M | 0.01% | 1449 |
|
|
2021
Q4 | $214M | Sell |
10,797,477
-1,073,041
| -9% | -$21.8M | ﹤0.01% | 1563 |
|
|
2021
Q3 | $234M | Sell |
11,870,518
-106,866
| -0.9% | -$2.24M | 0.01% | 1510 |
|
|
2021
Q2 | $264M | Sell |
11,977,384
-410,343
| -3% | -$9.13M | 0.01% | 1460 |
|
|
2021
Q1 | $295M | Buy |
12,387,727
+391,578
| +3% | +$10.5M | 0.01% | 1323 |
|
|
2020
Q4 | $314M | Buy |
11,996,149
+264,345
| +2% | +$5.57M | 0.01% | 1164 |
|
|
2020
Q3 | $204M | Buy |
11,731,804
+492,458
| +4% | +$7.85M | 0.01% | 1271 |
|
|
2020
Q2 | $189M | Buy |
11,239,346
+121,519
| +1% | +$1.71M | 0.01% | 1304 |
|
|
2020
Q1 | $132M | Buy |
11,117,827
+169,081
| +2% | +$2.09M | 0.01% | 1371 |
|
|
2019
Q4 | $132M | Buy |
10,948,746
+42,085
| +0.4% | +$586K | ﹤0.01% | 1617 |
|
|
2019
Q3 | $154M | Sell |
10,906,661
-41,458
| -0.4% | -$509K | 0.01% | 1493 |
|
|
2019
Q2 | $122M | Buy |
10,948,119
+12,558
| +0.1% | +$140K | ﹤0.01% | 1640 |
|
|
2019
Q1 | $128M | Buy |
10,935,561
+161,567
| +1% | +$2.01M | 0.01% | 1617 |
|
|
2018
Q4 | $144M | Buy |
10,773,994
+411,434
| +4% | +$5.44M | 0.01% | 1455 |
|
|
2018
Q3 | $145M | Buy |
10,362,560
+37,781
| +0.4% | +$528K | 0.01% | 1602 |
|
|
2018
Q2 | $162M | Buy |
10,324,779
+1,573,511
| +18% | +$27.4M | 0.01% | 1490 |
|
|
2018
Q1 | $144M | Sell |
8,751,268
-618,911
| -7% | -$11.5M | 0.01% | 1507 |
|
|
2017
Q4 | $169M | Buy |
9,370,179
+3,134,600
| +50% | +$56.8M | 0.01% | 1410 |
|
|
2017
Q3 | $120M | Buy |
6,235,579
+1,795,515
| +40% | +$26.8M | 0.01% | 1603 |
|
|
2017
Q2 | $52.4M | Buy |
4,440,064
+689,554
| +18% | +$7.5M | ﹤0.01% | 1997 |
|
|
2017
Q1 | $41.1M | Buy |
3,750,510
+359,177
| +11% | +$3.15M | ﹤0.01% | 2102 |
|
|
2016
Q4 | $24.6M | Buy |
3,391,333
+307,569
| +10% | +$2.41M | ﹤0.01% | 2328 |
|
|
2016
Q3 | $20M | Buy |
3,083,764
+104,029
| +3% | +$605K | ﹤0.01% | 2356 |
|
|
2016
Q2 | $16.3M | Buy |
2,979,735
+193,729
| +7% | +$1.01M | ﹤0.01% | 2417 |
|
|
2016
Q1 | $13M | Buy |
2,786,006
+25,697
| +0.9% | +$100K | ﹤0.01% | 2475 |
|
|
2015
Q4 | $13.7M | Buy |
2,760,309
+57,086
| +2% | +$257K | ﹤0.01% | 2464 |
|
|
2015
Q3 | $10.2M | Buy |
2,703,223
+75,636
| +3% | +$384K | ﹤0.01% | 2599 |
|
|
2015
Q2 | $15.8M | Buy |
2,627,587
+378,204
| +17% | +$2.32M | ﹤0.01% | 2455 |
|
|
2015
Q1 | $12.6M | Buy |
2,249,383
+47,087
| +2% | +$170K | ﹤0.01% | 2534 |
|
|
2014
Q4 | $6.61M | Buy |
2,202,296
+45,413
| +2% | +$138K | ﹤0.01% | 2747 |
|
|
2014
Q3 | $5.78M | Buy |
2,156,883
+8,639
| +0.4% | +$22.9K | ﹤0.01% | 2756 |
|
|
2014
Q2 | $6.02M | Buy |
2,148,244
+18,849
| +0.9% | +$55.6K | ﹤0.01% | 2746 |
|
|
2014
Q1 | $9.28M | Buy |
2,129,395
+222,944
| +12% | +$779K | ﹤0.01% | 2531 |
|
|
2013
Q4 | $6.14M | Sell |
1,906,451
-94,507
| -5% | -$191K | ﹤0.01% | 2684 |
|
|
2013
Q3 | $3.18M | Buy |
2,000,958
+20,184
| +1% | +$35.6K | ﹤0.01% | 2948 |
|
|
2013
Q2 | $3.43M | Buy |
+1,980,774
| New | +$3.56M | ﹤0.01% | 2867 |
|
Other funds holding CORT
ISL
PA
Vanguard Group's CORT Position: Q4 2025 in Review
Vanguard Group reduced its Corcept Therapeutics (CORT) stake by 0.44% in Q4 2025, selling an estimated $3.32M and leaving 9,494,822 shares worth $330M. The position accounts for ﹤0.01% of the portfolio, ranked #1288.
Vanguard Group first reported a position in CORT in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.14B in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.
- Vanguard Group held 9,494,822 shares of Corcept Therapeutics worth $330M as of Q4 2025.
- Vanguard Group sold 42,249 Corcept Therapeutics shares in Q4 2025, an estimated $3.32M.
- Corcept Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1288 holding.
- Vanguard Group first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Corcept Therapeutics position peaked at $1.14B in Q1 2025.
- 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.